ET
The startup is developing a non-hormonal therapeutic that targets a novel biochemical pathway involved in endometriosis, aiming to provide a disease-modifying treatment for affected individuals. This approach offers the potential for long-term remission from the debilitating symptoms associated with endometriosis.
Updated 3 months ago
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup is developing a non-hormonal therapeutic that targets a novel biochemical pathway involved in endometriosis, aiming to provide a disease-modifying treatment for affected individuals. This approach offers the potential for long-term remission from the debilitating symptoms associated with endometriosis.